# CRIP2

## Overview
CRIP2 (cysteine-rich protein 2) is a gene that encodes a LIM-domain-only protein involved in various cellular processes, including autophagy regulation, skeletal muscle differentiation, and cardiovascular development. The CRIP2 protein is characterized by its two LIM domains, which facilitate protein-protein interactions through zinc finger-like structures. It is a non-classical secretable protein, despite lacking a signal sequence and transmembrane domain, and is notably expressed in the heart and other tissues. CRIP2 plays a significant role in copper metabolism, acting as a nuclear copper-binding protein that influences its stability and degradation. It interacts with several proteins, such as PTP-BL and ADAM19, and acts as a transcriptional repressor of NF-κB-mediated pathways, impacting angiogenesis and tumorigenesis. Clinically, CRIP2 is implicated in various cancers, functioning as a tumor suppressor in some contexts and contributing to chemoresistance in others (Chen2021APEX2‐based; Ariës2018PRC2; Cheung2011Cysteinerich).

## Structure
CRIP2 (cysteine-rich protein 2) is characterized by the presence of two LIM domains, each containing zinc finger-like structures that coordinate with zinc ions. These LIM domains are defined by a cysteine-rich zinc-finger motif with the sequence C-X2-C-X16-23-H-X2-C-X2-C-X2-C-X16-21-C-X2-3-C/H/D, which facilitates protein-protein interactions (Tanabe2010ADAM19). The protein is capable of binding copper ions, which can displace zinc ions, potentially altering the stability and function of the zinc finger domains (Chen2021APEX2‐based). 

CRIP2's interaction with copper is mediated through cysteine residues, and copper binding induces changes in the protein's secondary structure, as evidenced by alterations in near-UV circular dichroism and electrophoretic mobility (Chen2021APEX2‐based). The binding of copper also enhances CRIP2's ubiquitination and degradation via the ubiquitin-proteasome system, suggesting a regulatory role in protein turnover (Chen2021APEX2‐based). 

CRIP2 lacks a classical signal sequence and transmembrane domain, yet it is identified as a non-classical secretable protein, with its secretion influenced by ADAM19, a metalloprotease (Tanabe2010ADAM19). The protein is expressed in various tissues, with notable expression in the heart (Tanabe2010ADAM19). However, specific details on the primary, tertiary, or quaternary structure of CRIP2 are not provided in the available context.

## Function
CRIP2, a LIM-domain-only protein, plays a significant role in various cellular processes, including autophagy regulation and skeletal muscle differentiation. In healthy human cells, CRIP2 functions as a nuclear copper-binding protein that regulates autophagy activation. It binds copper ions, which affects its stability and leads to its degradation via the ubiquitin-proteasome system. This degradation process is linked to the suppression of autophagy, as CRIP2 knockdown results in increased levels of LC3II, a marker of autophagy (Chen2021APEX2‐based).

CRIP2 is also involved in skeletal muscle differentiation, acting as a copper-responsive regulator. It binds copper and zinc ions, with a higher affinity for copper, and influences transcription regulation in mammalian cells. CRIP2 associates with gene promoters like MyoD1 and metallothioneins, playing a crucial role in muscle differentiation by affecting mRNA processing, protein translation, and chromatin organization (VerdejoTorres2024Cysteine).

CRIP2 is expressed in the cardiovascular system, particularly in the myocardium and endocardium, and is involved in cardiovascular development and homeostasis. It interacts with proteins like PTP-BL and ADAM19, suggesting a role in mediating protein-protein interactions and signaling pathways (Wei2011Expression).

## Clinical Significance
CRIP2 (cysteine-rich protein 2) has been implicated in various cancers due to alterations in its expression levels. It is identified as a tumor suppressor gene, with significant down-regulation observed in nasopharyngeal carcinoma (NPC), breast cancer, and esophageal squamous cell carcinoma. In NPC, CRIP2 down-regulation is associated with tumor progression, and its reexpression has been shown to suppress tumorigenesis and angiogenesis (Cheung2011Cysteinerich). In breast cancer, CRIP2 expression is suppressed by miR-449a, leading to increased tumor growth, migration, and invasion, as well as enhanced angiogenic signaling through the NF-κB/p65 complex (Shi2016MiR449a).

In T cell acute lymphoblastic leukemia (T-ALL), CRIP2 is up-regulated following the loss of PRC2 function, contributing to chemoresistance by inducing TRAP1 expression, which is associated with resistance to apoptosis (Ariës2018PRC2). This suggests that CRIP2 plays a role in mediating resistance to chemotherapy in T-ALL, impacting patient prognosis.

In colon cancer, CRIP2 expression levels are correlated with risk scores, although its exact role remains to be further elucidated (Zhang2020Identification). These findings highlight the clinical significance of CRIP2 in cancer biology, where its altered expression or interaction with other molecules can influence disease progression and treatment outcomes.

## Interactions
CRIP2, a LIM domain protein, engages in several protein-protein interactions that influence its function in cellular processes. It interacts with the PDZ domains of the protein tyrosine phosphatase PTP-BL, specifically binding to the fourth PDZ domain (PDZ-IV). This interaction is mediated by the LIM domains of CRIP2 and does not require the C-terminal amino acids, indicating a non-classical binding mode (Van2003Cloning). CRIP2 also interacts with the NF-κB/p65 subunit, acting as a transcriptional repressor to inhibit NF-κB-mediated proangiogenic cytokine transcription, which plays a role in suppressing angiogenesis and tumorigenesis (Cheung2011Cysteinerich).

CRIP2 is involved in copper metabolism through its interaction with the copper chaperone Atox1. Atox1 transfers copper to CRIP2, leading to changes in CRIP2's structure and its subsequent degradation, which affects autophagy activation in cancer cells (Chen2021APEX2‐based). Additionally, CRIP2 binds to ADAM19, a metalloprotease, through its DI and cysteine-rich domains, independent of ADAM19's catalytic activity. This interaction is part of a non-classical secretory pathway influenced by external stimuli like LPS (Tanabe2010ADAM19).


## References


[1. (Tanabe2010ADAM19) Chiaki Tanabe, Nika Hotoda, Noboru Sasagawa, Eugene Futai, Hiroto Komano, and Shoichi Ishiura. Adam19 autolysis is activated by lps and promotes non-classical secretion of cysteine-rich protein 2. Biochemical and Biophysical Research Communications, 396(4):927–932, June 2010. URL: http://dx.doi.org/10.1016/j.bbrc.2010.05.025, doi:10.1016/j.bbrc.2010.05.025. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2010.05.025)

[2. (Wei2011Expression) Tzu-Chieh Wei, Hui-Yu Lin, Cheng-Chieh Lu, Chun-Ming Chen, and Li-Ru You. Expression of crip2, a lim-domain-only protein, in the mouse cardiovascular system under physiological and pathological conditions. Gene Expression Patterns, 11(7):384–394, October 2011. URL: http://dx.doi.org/10.1016/j.gep.2011.05.001, doi:10.1016/j.gep.2011.05.001. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gep.2011.05.001)

[3. (Van2003Cloning) Marco Van Ham, Huib Croes, Jan Schepens, Jack Fransen, Bé Wieringa, and Wiljan Hendriks. Cloning and characterization of mcrip2, a mouse lim‐only protein that interacts with pdz domain iv of ptp‐bl. Genes to Cells, 8(7):631–644, July 2003. URL: http://dx.doi.org/10.1046/j.1365-2443.2003.00660.x, doi:10.1046/j.1365-2443.2003.00660.x. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1046/j.1365-2443.2003.00660.x)

[4. (Cheung2011Cysteinerich) Arthur Kwok Leung Cheung, Josephine M. Y. Ko, Hong Lok Lung, Kwok Wah Chan, Eric J. Stanbridge, Eugene Zabarovsky, Takashi Tokino, Lisa Kashima, Toshiharu Suzuki, Dora Lai-Wan Kwong, Daniel Chua, Sai Wah Tsao, and Maria Li Lung. Cysteine-rich intestinal protein 2 ( crip2 ) acts as a repressor of nf-κb–mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis. Proceedings of the National Academy of Sciences, 108(20):8390–8395, May 2011. URL: http://dx.doi.org/10.1073/pnas.1101747108, doi:10.1073/pnas.1101747108. This article has 63 citations.](https://doi.org/10.1073/pnas.1101747108)

5. (VerdejoTorres2024Cysteine) Cysteine Rich Intestinal Protein 2 is a copper-responsive regulator of skeletal muscle differentiation. This article has 0 citations.

[6. (Zhang2020Identification) Xuening Zhang, Hao Zhao, Xuezhong Shi, Xiaocan Jia, and Yongli Yang. Identification and validation of an immune-related gene signature predictive of overall survival in colon cancer. Aging, 12(24):26095–26120, December 2020. URL: http://dx.doi.org/10.18632/aging.202317, doi:10.18632/aging.202317. This article has 34 citations and is from a peer-reviewed journal.](https://doi.org/10.18632/aging.202317)

[7. (Chen2021APEX2‐based) Lin Chen, Na Li, Meiqi Zhang, Mingming Sun, Jiaxuan Bian, Bo Yang, Zhengcunxiao Li, Jiayu Wang, Fei Li, Xiaomeng Shi, Yuan Wang, Feng Yuan, Peng Zou, Changliang Shan, and Jing Wang. Apex2‐based proximity labeling of atox1 identifies crip2 as a nuclear copper‐binding protein that regulates autophagy activation. Angewandte Chemie, 133(48):25550–25559, October 2021. URL: http://dx.doi.org/10.1002/ange.202108961, doi:10.1002/ange.202108961. This article has 0 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/ange.202108961)

[8. (Ariës2018PRC2) Ingrid M. Ariës, Kimberly Bodaar, Salmaan A. Karim, Triona Ni Chonghaile, Laura Hinze, Melissa A. Burns, Maren Pfirrmann, James Degar, Jack T. Landrigan, Sebastian Balbach, Sofie Peirs, Björn Menten, Randi Isenhart, Kristen E. Stevenson, Donna S. Neuberg, Meenakshi Devidas, Mignon L. Loh, Stephen P. Hunger, David T. Teachey, Karen R. Rabin, Stuart S. Winter, Kimberly P. Dunsmore, Brent L. Wood, Lewis B. Silverman, Stephen E. Sallan, Pieter Van Vlierberghe, Stuart H. Orkin, Birgit Knoechel, Anthony G. Letai, and Alejandro Gutierrez. Prc2 loss induces chemoresistance by repressing apoptosis in t cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 215(12):3094–3114, November 2018. URL: http://dx.doi.org/10.1084/jem.20180570, doi:10.1084/jem.20180570. This article has 34 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1084/jem.20180570)

[9. (Shi2016MiR449a) Wei Shi, Jeff Bruce, Matthew Lee, Shijun Yue, Matthew Rowe, Melania Pintilie, Ryunosuke Kogo, Pierre-Antoine Bissey, Anthony Fyles, Kenneth W. Yip, and Fei-Fei Liu. Mir-449a promotes breast cancer progression by targeting crip2. Oncotarget, 7(14):18906–18918, February 2016. URL: http://dx.doi.org/10.18632/oncotarget.7753, doi:10.18632/oncotarget.7753. This article has 44 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.7753)